The next step for health care professionals is to teach patients how to act on the data collected by intermittently scanned glucose sensing technologies, according to Viral Shah, MD, an endocrinologist and scientist.
When it comes to diabetes technologies, the combination of the correct use, by the correct patients, in the correct manner is what leads to good outcomes, said Viral Shah, MD, endocrinologist and associate professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, Adult Clinic School of Medicine at the University of Colorado Anschutz campus.
Transcript
What are the more common reasons why patients might fail to achieve optimal glycemic control even while using these technologies?
This is another excellent question. I give this analogy like, OK, I have an iPhone, an iWatch, but I don't use every single function in that. That means I'm not optimally using that. Similarly, in the diabetes technology space, if you do not use that optimally, you're not going to achieve the optimal outcomes. A couple of examples for that is many patients with type 1 or type 2 diabetes who are on intermittently scanned glucose sensing technologies, where you have to scan it, if you don't scan it, you don't see the number. And if you don't see the number, you're not going to make any action.
Ultimately, it's not about the use of technology, but the right use of a technology in the right patient, in the right manner, that leads to a good outcome. So I think all the health care professionals and everybody needs to not just the promote the technology, but also advise the patient on how to use it, how to review the data meaningfully, how to act based on the data. And if you don't act, you're not going to achieve the good results. So I think with the promotion of diabetes technology, the next step for us is now teaching our patients how to act on those data, and I think that will help to optimize the outcome.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
2 Commerce Drive
Cranbury, NJ 08512